Compare Stocks → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNYSE:ANVSNASDAQ:BLPHNASDAQ:EVOKNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsANVSAnnovis Bio$11.63-3.3%$10.19$5.42▼$23.89$123.05M1.55285,025 shs174,961 shsBLPHBellerophon Therapeutics$0.06$0.06$0.03▼$12.58$695K0.6732,450 shs1,066 shsEVOKEvoke Pharma$0.60+2.2%$0.67$0.56▼$2.42$5.09M0.2163,645 shs26,475 shsJAGXJaguar Health$0.08+10.6%$0.08$0.05▼$1.22$4.09M1.3138.28 million shs30.30 million shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-90.37%ANVSAnnovis Bio+0.42%+7.80%+34.72%-38.91%-39.03%BLPHBellerophon Therapeutics-1.60%+11.18%+6.69%+67.10%-99.24%EVOKEvoke Pharma+0.05%+2.02%-3.95%-45.00%-71.46%JAGXJaguar Health+5.65%-8.76%+21.50%-54.97%-90.65%AI to Meet the Same Fate as EVs? (Ad)When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio2.3736 of 5 stars3.43.00.00.02.91.70.6BLPHBellerophon Therapeutics1.8054 of 5 stars3.20.00.04.81.90.00.6EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/AANVSAnnovis Bio2.75Moderate Buy$27.75138.61% UpsideBLPHBellerophon Therapeutics2.33Hold$2.003,420.20% UpsideEVOKEvoke PharmaN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest ADMP, BLPH, JAGX, ANVS, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.0012/29/2023ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.0012/29/2023ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00ANVSAnnovis BioN/AN/AN/AN/A$3.47 per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/AEVOKEvoke Pharma$5.18M0.98N/AN/A($0.77) per share-0.78JAGXJaguar Health$11.96M0.34N/AN/A($0.32) per share-0.25Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/AANVSAnnovis Bio-$25.33M-$4.27N/AN/AN/AN/A-195.55%-156.80%4/1/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%3/29/2024 (Estimated)EVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)JAGXJaguar Health-$47.45MN/A0.00N/AN/A-370.40%-1,191.67%-79.95%4/1/2024 (Confirmed)Latest ADMP, BLPH, JAGX, ANVS, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024N/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/A 3/29/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19ANVSAnnovis BioN/A2.872.87BLPHBellerophon TherapeuticsN/A3.963.96EVOKEvoke Pharma9.292.252.09JAGXJaguar Health22.001.771.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%ANVSAnnovis Bio15.83%BLPHBellerophon Therapeutics10.61%EVOKEvoke PharmaN/AJAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%ANVSAnnovis Bio38.30%BLPHBellerophon Therapeutics5.20%EVOKEvoke Pharma11.78%JAGXJaguar Health0.16%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableANVSAnnovis Bio510.58 million6.53 millionOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableJAGXJaguar Health6050.76 million50.68 millionNo DataADMP, BLPH, JAGX, ANVS, and EVOK HeadlinesSourceHeadlineJaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updatesaccesswire.com - March 27 at 8:30 AMJaguar Health (NASDAQ:JAGX) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - March 21 at 2:16 AMGEN to Commercialize Jaguar Health's Crofelemer in…pharmiweb.com - March 20 at 3:50 PMJaguar Health, Inc.edition.cnn.com - March 20 at 3:50 PMGEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Marketfinance.yahoo.com - March 20 at 3:50 PMCapricor Therapeutics, Inc. (4LN2.F)finance.yahoo.com - March 15 at 6:58 PMJaguar Health balances ambitions for human and animal pharmaceuticalspharmaceutical-technology.com - March 12 at 3:06 PMWhat In The World Is Going On With Jaguar Health (JAGX) Stock?msn.com - March 1 at 1:22 PMJaguar Health, Inc.: Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliancefinanznachrichten.de - February 23 at 1:20 PMJaguar Health Requests and Receives Hearing on Nasdaq Listing Complianceaccesswire.com - February 23 at 8:30 AMJaguar Health Incmoney.usnews.com - February 17 at 7:59 PMJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogsfinance.yahoo.com - February 15 at 10:02 AMJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogsaccesswire.com - February 15 at 8:30 AMJaguar Health, Inc.: Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relieffinanznachrichten.de - February 14 at 7:03 PMJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relieffinance.yahoo.com - February 14 at 9:03 AMJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Reliefaccesswire.com - February 14 at 8:30 AMJaguar Health, Inc. (JAGX)ca.finance.yahoo.com - February 12 at 10:59 AMJaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrheafinance.yahoo.com - February 12 at 10:59 AMJaguar Health Inc (JAGX)investing.com - January 31 at 10:06 AM'Rainforests Are Nature's Medicine Cabinets': Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challengesmsn.com - January 30 at 3:13 PMMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regionsfinance.yahoo.com - January 30 at 10:12 AMJaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conferencefinance.yahoo.com - January 29 at 1:35 PMDog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)finance.yahoo.com - January 25 at 10:46 AMJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - January 22 at 1:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Annovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.